NCT01624441View on ClinicalTrials.gov

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 21, 2012

Primary Completion Date

September 10, 2013

Study Completion Date

September 10, 2013

Conditions
Estrogen Receptor NegativeHER2/Neu NegativeMale Breast CarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7Triple-Negative Breast Carcinoma
Interventions
DRUG

Dinaciclib

Given IV

DRUG

Epirubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01624441 - Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter